Contact
Please use this form to send email to PR contact of this press release:
Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer
TO: